Leaflet ZYDELIG 150mg film-coated tablets
- Product code:
- W63550001
- Quantity:
- 60
- Indicated for:
- hematologic malignancies
- Route of administration:
- oral
- Substance:
- idelalisib (kinase inhibitor)
- ATC
- L01EM01 — Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Phosphatidylinositol-3-kinase (PI3K) inhibitors
Idelalisib is a medication used to treat certain types of blood cancer, such as chronic lymphocytic leukemia (CLL) and follicular lymphoma. It is a PI3K-delta kinase inhibitor, which plays a key role in the survival and proliferation of cancer cells.
The medication is taken orally, usually twice daily, as directed by a doctor.
Side effects may include diarrhea, nausea, fever, fatigue, or infections. In rare cases, severe adverse effects such as hepatotoxicity or pneumonitis may occur.
Patients should be closely monitored during treatment and inform their doctor about any other medications they are taking. Pregnant or breastfeeding women should consult a specialist before use.
The medication is taken orally, usually twice daily, as directed by a doctor.
Side effects may include diarrhea, nausea, fever, fatigue, or infections. In rare cases, severe adverse effects such as hepatotoxicity or pneumonitis may occur.
Patients should be closely monitored during treatment and inform their doctor about any other medications they are taking. Pregnant or breastfeeding women should consult a specialist before use.
General data about ZYDELIG 150mg
- Substance:
- idelalisib
- Date of latest medicines list:
- 16-08-2017
- Product code:
- W63550001
- Concentration:
- 150mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 60
- Product type:
- Original
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Concentrations available for idelalisib
- 100mg
- 150mg